...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cardiology >Overview of complications during pharmacological spasm provocation tests
【24h】

Overview of complications during pharmacological spasm provocation tests

机译：药理痉挛激发试验中并发症的概述

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pharmacological spasm provocation tests are invasive methods and we always have the potential to encounter complications when performing these tests. In 1980, Buxton et al. reported three deaths when they performed intravenous ergonovine testing. However, we now employ the intracoronary ergonovine test instead of the intravenous injection of ergonovine from a safety procedure point of view. Past serious major complications of intravenous ergonovine tests, intracoronary ergonovine tests, and intracoronary acetylcholine tests were 0.31% (26/8419), 0.51% (11/2173), and 0.95% (148/15,527), respectively. Selective intracoronary testing had the serious major complications in 0.89% of patients including just one death (0.006%) and two acute myocardial infarctions (0.01%). Selective spasm provocation tests had no additional risks compared with performing diagnostic coronary angiography alone. In the Western countries, the pharmacological spasm provocation tests are not familiar in the clinic except for some specialized institutions. We need international clinical studies using the same protocol of spasm provocation tests to compare the frequency, clinical features, and prognosis of acetylcholine- or ergonovine-provoked coronary spasm between Western and Asian countries. And we hope that Western guidelines give spasm provocation testing a class I indication similar to Japanese Circulation Society guidelines because coronary artery spasm may have fewer racial differences and borders. (C) 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
机译：药理痉挛激发试验是一种侵入性方法，在进行这些试验时，我们总是有可能遇到并发症。 1980年，Buxton等人。他们进行静脉麦角新碱测试时报告三例死亡。但是，从安全程序的角度来看，我们现在采用冠状动脉内麦角新碱试验，而不是静脉内注射麦角新碱。过去的静脉麦角新碱试验，冠状动脉内麦角新碱试验和冠状动脉内乙酰胆碱试验的严重并发症分别为0.31％（26/8419），0.51％（11/2173）和0.95％（148 / 15,527）。选择性冠状动脉内检查在0.89％的患者中具有严重的严重并发症，包括仅1例死亡（0.006％）和2例急性心肌梗塞（0.01％）。与仅进行诊断性冠状动脉造影相比，选择性痉挛激发试验没有其他风险。在西方国家，除了一些专门机构外，药理痉挛激发试验在诊所并不为人所知。我们需要使用相同的痉挛激发试验方案进行国际临床研究，以比较西方和亚洲国家之间由乙酰胆碱或麦角新碱引起的冠状动脉痉挛的发生频率，临床特征和预后。并且我们希望西方指南能够为痉挛激发试验提供类似于日本循环协会指南的I类适应症，因为冠状动脉痉挛可能具有较少的种族差异和边界。 （C）2016年日本心脏病学院。由Elsevier Ltd.出版。保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号